Fate Therapeutics (FATE) has issued an update.
Fate Therapeutics, Inc. has expanded its Board of Directors by appointing Dr. Neelufar Mozaffarian, an experienced medical professional with a background in AI-driven clinical development and immune homeostasis therapy, effective July 29, 2024. This decision follows her significant contributions at Atomwise Inc. and other leading pharmaceutical companies. Dr. Mozaffarian’s expertise is expected to fortify the Board’s scientific and technological acumen as she takes on her role, with an added incentive of stock options to align her interests with the company’s success.
See more data about FATE stock on TipRanks’ Stock Analysis page.
